Pholcodine

Last updated

Pholcodine
Pholcodine2DCSD.svg
Pholcodine3DanJ.gif
Clinical data
Trade names Logicin, others
AHFS/Drugs.com International Drug Names
Addiction
liability 		High
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Maximum plasma conc. attained 4-8 hours after oral dose.
Protein binding 23.5%
Metabolism Liver
Elimination half-life 32-43 hours; volume of distribution is 36-49L/kg.
Excretion Kidney
Identifiers
  • 7,8-Didehydro-4,5α-epoxy-17-methyl-3-[2-(morpholin-4-yl)ethoxy]morphinan-6α-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.007.367 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C23H30N2O4
Molar mass 398.503 g·mol−1
3D model (JSmol)
  • O(c5ccc4c1c5O[C@H]3[C@@H](O)\C=C/[C@H]2[C@H](N(C)CC[C@@]123)C4)CCN6CCOCC6
  • InChI=1S/C23H30N2O4/c1-24-7-6-23-16-3-4-18(26)22(23)29-21-19(5-2-15(20(21)23)14-17(16)24)28-13-10-25-8-11-27-12-9-25/h2-5,16-18,22,26H,6-14H2,1H3/t16-,17+,18-,22-,23-/m0/s1
  • Key:GPFAJKDEDBRFOS-FKQDBXSBSA-N

Pholcodine is an opioid cough suppressant (antitussive). It helps suppress unproductive coughs and also has a mild sedative effect, but has little or no analgesic effects. It is also known as morpholinylethylmorphine and homocodeine.

Contents

Pholcodine is found in certain cough lozenges, [2] and more commonly as an oral solution, typically 5 mg / 5 ml. Adult dosage is 5-10 ml up to 3-4 times daily. [3] Pholcodine now largely replaces the previously more common codeine linctus, as it has a much lower potential for dependence.

Pholcodine has been widely used as an antitussive agent but by 2023 concerns over its association with anaphylaxis in some circumstances meant that it has been withdrawn from sale in many territories. Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug, the most highly controlled drug category. [4]

Following the conclusion of a review of post-marketing safety data by the MHRA, all pholcodine-containing medicines are being recalled and withdrawn from the UK as a precaution. [5] The available data has demonstrated that pholcodine use, particularly in the twelve months before general anesthesia with NMBAs (neuromuscular blocking agents), is a risk factor for developing an anaphylactic reaction to NMBAs. In December 2022, the European Medicines Agency recommended their withdrawal in the EU. [6] As of February 2023, the Australian Therapeutic Goods Administration canceled the registration of pholcodine. [7] [8]

Mechanism of action

Pholcodine is readily absorbed from the gastrointestinal tract and freely crosses the blood–brain barrier. It acts primarily on the central nervous system (CNS), causing depression of the cough reflex, partly by a direct effect on the cough centre in the medulla. It is metabolized in the liver and its action may be prolonged in individuals with hepatic insufficiency (i.e. liver problems). Its use is therefore contraindicated in patients with liver disease, while care is advised in patients with hepatic impairment.

Metabolism and excretion

Pholcodine is slowly biotransformed in the body via oxidation and conjugation to a series of metabolites that are eliminated primarily in the urine. With an average half-life of approximately 2.3 days, steady-state in someone taking the drug chronically would not be reached for nearly 2 weeks. Nearly one-half of a single dose is eventually excreted as free or conjugated parent drug. The most important urinary metabolite is conjugated morphine, which may be detectable for days or weeks after the last dose. This could trigger a positive result for opiates in a urine drug testing program. [9] [10]

Side effects

Side effects are rare and may include dizziness and gastrointestinal disturbances such as nausea or vomiting. Adverse effects such as constipation, drowsiness, excitation, ataxia and respiratory depression have been reported occasionally or after large doses. The primary safety concerns with pholcodine revolve around death during general anaesthesia. [11]

Anaphylaxis during general anaesthesia

Administration of pholcodine causes production of antibodies linked with fatalities during surgery, when essential neuromuscular blocking agents (NMBAs) are administered to prevent patient movement under general anaesthesia. [12] These antibody levels gradually fall to low levels several years after last dose of pholcodine. However, the presence of these antibodies causes a 300-fold increase in risk of anaphylaxis during anaesthesia. [13]

The link was suspected when neighbouring Norway and Sweden were found to have tenfold differences of surgical anaphylaxis deaths. Sweden had no products approved containing pholcodine, whereas 40% of the population in Norway had consumed the single approved pholcodine product. [13] Norway withdrew pholcodine from the market in 2007, and the prevalence of anti-suxamethonium antibodies fell by over 80% in two years. [14] A corresponding fall in anaesthesia deaths followed. [13]

A similar disparity exists between NMBA anaphylaxis rates in Australia, where pholcodine consumption is high and the US, where pholcodine is banned. [15] In the US, anaphylaxis rates are so low that some anaesthetists question the existence of such reactions to NMBAs. [16] Conversely, Australian anaesthetists have requested a ban on pholcodine [17] due to the high anaphylaxis rate in the country. [18] However, the Therapeutic Goods Administration declined the request in January 2015, [19] pending further reviews to follow. In February 2023, the Therapeutic Goods Administration reversed its previous decision and banned products containing pholcodine. [20]

In contrast, the European Medicines Agency's 2012 "Assessment report for Pholcodine containing medicinal products" concludes this: The Committee considered that evidence of an association between pholcodine use and development of NMBA-related anaphylaxis is circumstantial, not entirely consistent and therefore does not support the conclusion that there is a significant risk of cross-sensitisation to NMBAs and subsequent development of anaphylaxis during surgery. [21]

In September 2022, the European Medicines Agency (EMA) started reviewing its position [22] at the request of the French ANSM, which withdrew all pholcodine-containing medicines [23] after preliminary results from a local study showed an increased risk of anaphylaxis after pholcodine use. [24] The EMA review concluded on 14 December 2022 with the recommendation that pholcodine be withdrawn from the EU market. [25] This decision was ratified by the European Commission in March 2023. [26] The UK government recalled all products containing pholcodine in March 2023. [27]

Related Research Articles

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection. It works by inactivating tumor necrosis factor-alpha (TNFα).

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.

<span class="mw-page-title-main">Amfepramone</span> Stimulant drug used as an appetite suppressant

Amfepramone, also known as diethylpropion, is a stimulant drug of the phenethylamine, amphetamine, and cathinone classes that is used as an appetite suppressant. It is used in the short-term management of obesity, along with dietary and lifestyle changes. Amfepramone has a similar chemical structure to the antidepressant and smoking cessation aid bupropion, which has also been developed as a weight-loss medicine when in a combination product with naltrexone.

<span class="mw-page-title-main">Tremelimumab</span> Monoclonal antibody

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

<span class="mw-page-title-main">Fibrin glue</span> Pharmaceutical compound

Fibrin glue is a surgical formulation used to create a fibrin clot for hemostasis, cartilage repair surgeries or wound healing. It contains separately packaged human fibrinogen and human thrombin.

<span class="mw-page-title-main">Umeclidinium bromide/vilanterol</span> Pharmaceutical medication

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD). It is administered by inhalation.

<span class="mw-page-title-main">Sacituzumab govitecan</span> Antibody-drug conjugate

Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.

Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein.

Pegvaliase, sold under the brand name Palynziq, is a medication used for the treatment of the genetic disease phenylketonuria (PKU). It is a phenylalanine (Phe)‑metabolizing enzyme. Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.

<span class="mw-page-title-main">Hexavalent vaccine</span> Single vaccine protecting against six individual diseases

A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.

<span class="mw-page-title-main">Faricimab</span> Medication for macular degeneration

Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection by an ophthalmologist.

Imlifidase, brand name Idefirix, is a medication for the desensitization of highly sensitized adults needing kidney transplantation, but unlikely to receive a compatible transplant.

Pralsetinib, sold under the brand name Gavreto, is a medication approved for RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy. Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.

<span class="mw-page-title-main">Relugolix/estradiol/norethisterone acetate</span> Combination medication

Relugolix/estradiol/norethisterone acetate, sold under the brand names Myfembree and Ryeqo, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and for moderate to severe pain associated with endometriosis. It contains relugolix, an orally active gonadotropin-releasing hormone antagonist, estradiol, an estrogen, and norethisterone acetate, a progestin. The medication is taken by mouth.

<span class="mw-page-title-main">Tixagevimab/cilgavimab</span> Monoclonal antibody treatment for COVID-19

Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections.

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion.

<span class="mw-page-title-main">Deucravacitinib</span> Chemical compound

Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.

References

  1. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 3 August 2023.
  2. ↑ "Potter's Pholcodine cough pastilles". Lloyds Pharmacy. Archived from the original on 29 February 2020. Retrieved 29 February 2020.
  3. ↑ British National Formulary 54. London: BMJ Publishing Group Ltd., RPS Publishing. 2007. p. 175.
  4. ↑ "Legislation - Controlled Substances". U.S. Food and Drug Administration (FDA). 11 June 2009. Archived from the original on 4 February 2016.
  5. ↑ "Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure". GOV.UK. 23 March 2023. Archived from the original on 11 November 2023. Retrieved 11 November 2023.
  6. ↑ "EMA recommends withdrawal of pholcodine medicines from EU market". European Medicines Agency (EMA). 2 December 2022. Archived from the original on 8 February 2024. Retrieved 8 February 2024.
  7. ↑ "Pholcodine". Therapeutic Goods Administration (TGA). 28 February 2023. Archived from the original on 18 May 2024. Retrieved 18 May 2024.
  8. ↑ "About pholcodine cough medicines cancelled by the TGA and recalled from pharmacies for safety reasons". Therapeutic Goods Administration (TGA). 1 March 2023. Archived from the original on 18 May 2024. Retrieved 18 May 2024.
  9. ↑ Maurer HH, Fritz CF (December 1990). "Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay, and gas chromatography-mass spectrometry". International Journal of Legal Medicine. 104 (1): 43–6. doi:10.1007/BF01816483. PMID   11453092. S2CID   5935454.
  10. ↑ Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 1258–1260.
  11. ↑ Andalo D (17 January 2015). "Anaesthetists campaign for pholcodine cough medicines to become prescription-only products". The Pharmaceutical Journal. Royal Pharmaceutical Society. Archived from the original on 17 September 2016. Retrieved 17 September 2016.
  12. ↑ Florvaag E, Johansson SG (August 2009). "The pholcodine story". Immunology and Allergy Clinics of North America. 29 (3): 419–27. doi:10.1016/j.iac.2009.04.002. PMID   19563989.
  13. 1 2 3 Florvaag E, Johansson SG (July 2012). "The Pholcodine Case. Cough Medicines, IgE-Sensitization, and Anaphylaxis: A Devious Connection". The World Allergy Organization Journal. 5 (7): 73–8. doi:10.1097/WOX.0b013e318261eccc. PMC   3651177 . PMID   23283141.
  14. ↑ Florvaag E, Johansson SG, Irgens Å, de Pater GH (July 2011). "IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market". Allergy. 66 (7): 955–60. doi:10.1111/j.1398-9995.2010.02518.x. PMID   21241314. S2CID   21048759.
  15. ↑ Sadleir PH, Clarke RC, Bunning DL, Platt PR (June 2013). "Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011". British Journal of Anaesthesia. 110 (6): 981–7. doi: 10.1093/bja/aes506 . PMID   23335568.
  16. ↑ Levy JH (April 2004). "Anaphylactic reactions to neuromuscular blocking drugs: are we making the correct diagnosis?". Anesthesia and Analgesia. 98 (4): 881–2. doi: 10.1213/01.ANE.0000115146.70209.4B . PMID   15041566.
  17. ↑ Crilly H, Rose M (2014). "Anaphylaxis and anaesthesia–can treating a cough kill?". Australian Prescriber. 37 (3): 74–76. doi: 10.18773/austprescr.2014.032 .
  18. ↑ Katelaris CH, Kurosawa M, Moon HB, Borres M, Florvaag E, Johansson SG (April 2014). "Pholcodine consumption and immunoglobulin E-sensitization in atopics from Australia, Korea, and Japan". Asia Pacific Allergy. 4 (2): 86–90. doi:10.5415/apallergy.2014.4.2.86. PMC   4005347 . PMID   24809013.
  19. ↑ Medew J (5 January 2015). "Cough medicine alert over surgery". The Age. Archived from the original on 7 January 2015. Retrieved 5 January 2015.
  20. ↑ "Pholcodine cough medicines cancelled by the TGA and recalled from pharmacies for safety reasons". Therapeutic Goods Administration. Archived from the original on 28 February 2023. Retrieved 28 February 2023.
  21. ↑ "Assessment report for Pholcodine containing medicinal products" (PDF). European Medicines Agency. 17 February 2012. Archived from the original (PDF) on 16 December 2017. Retrieved 24 March 2017.
  22. ↑ "Review of pholcodine medicines started". European Medicines Agency. 9 February 2022. Archived from the original on 13 October 2022. Retrieved 13 October 2022.
  23. ↑ "Pholcodine: Suspension des autorisations de mise sur le marché et retrait de toutes les boîtes de sirop contenant de la pholcodine en raison d'un risque d'allergie croisée avec les curares" [Pholcodine: Suspension of marketing authorizations and withdrawal of all boxes of syrup containing pholcodine due to a risk of cross allergy with curares]. Agence nationale de sécurité du médicament et des produits de santé (ANSM)[National Agency for the Safety of Medicines and Health Products] (in French). Archived from the original on 13 October 2022. Retrieved 13 October 2022.
  24. ↑ "Rationale for the Triggering of Procedure Under Article 107i of Directive 2001/83/EE on Pholcodine" (PDF). French Competent Authority (ANSM - French National Agency for Medicines and Health Products Safety) Agence nationale de sécurité du médicament et des produits de santé. August 2022. Archived (PDF) from the original on 12 October 2022. Retrieved 13 October 2022.
  25. ↑ "EMA recommends withdrawal of pholcodine medicines from EU market". European Medicines Agency. 1 December 2022. Archived from the original on 20 December 2022. Retrieved 20 December 2022.
  26. ↑ "Pholcodine medicines withdrawn from EU market" (PDF). European Medicines Agency. 6 March 2023. Archived (PDF) from the original on 5 April 2023. Retrieved 3 July 2023.
  27. ↑ Medicines and Healthcare products Regulatory Agency (14 March 2023). "Class 2 Medicines Recall: Various Marketing Authorisation Holders, pholcodine-containing products, EL (23)A/09". Archived from the original on 14 March 2023. Retrieved 14 March 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.